Trenabol Hexa
Overview
Trenabol Hexa British Dragon delivers trenbolone hexahydrobenzylcarbonate (parabolan) at 100 mg/ml in a 10 ml multidose vial — 1,000 mg total. Hexahydrobenzylcarbonate is the longest-acting trenbolone ester in current production, with a half-life of approximately 14 days. This allows once- or twice-weekly injection schedules and produces stable blood levels over 10–14 week cycles — without the EOD injection burden of Trenabol 100 BD (trenbolone acetate). The hexahydrobenzylcarbonate ester is historically significant: it is the ester used in Parabolan by Negma (France), the only pharmaceutical-grade human trenbolone product ever commercially manufactured, discontinued in 1997. All trenbolone hexa available today is manufactured by UGL sources. Steroid Warehouse carries Trenabol Hexa BD alongside the full British Dragon trenbolone range for athletes selecting ester format based on cycle length and injection frequency preference.
About the Compound
Trenbolone hexahydrobenzylcarbonate shares the same base molecule as trenbolone acetate and trenbolone enanthate: the 19-Nor androgen with a double bond between C9 and C10, high androgen receptor affinity (approximately 5× that of testosterone), and complete resistance to aromatase. The hexahydrobenzylcarbonate ester is a cyclohexylmethylcarbonate group attached at the C17-beta hydroxyl, producing a significantly larger and more lipophilic ester than acetate or enanthate. This extended lipophilicity slows ester hydrolysis and depot release, resulting in a half-life of approximately 14 days — the longest among the three clinically used trenbolone esters.
The pharmacological consequence is a flat, stable blood level curve between injections. A twice-weekly injection protocol (e.g. Monday and Thursday) at 300 mg/week produces smaller peak-to-trough swings than the same weekly dose of trenbolone acetate injected EOD, and the steady-state plateau is reached after approximately 3–4 weeks (vs ~5–7 days for acetate). The tradeoff is exit kinetics: following the last injection, trenbolone levels remain measurable for 3–4 weeks, and PCT cannot begin until the compound has cleared — typically 14–21 days post-last-injection. This is the defining operational difference between hexa and acetate, and it determines which format is appropriate for each user's situation.
What It Does
- Stable supraphysiologic trenbolone levels throughout the cycle: twice-weekly dosing with the ~14-day hexa ester maintains consistent trenbolone concentrations between injections, avoiding the blood level valleys that can occur with acetate if an EOD injection is missed; stable levels produce consistent AR stimulation, consistent prolactin behaviour, and more predictable side-effect expression — whether that is beneficial (consistent conditioning) or requires management (consistent cabergoline dosing).
- Dry lean mass accretion and nutrient partitioning: same anabolic mechanism as acetate once the ester cleaves; trenbolone's high AR affinity drives protein synthesis and nitrogen retention without aromatization; the absence of estrogen from the trenbolone component means no glycogen-driven water weight; at a caloric maintenance or mild deficit, the partitioning effect directs amino acids toward muscle protein synthesis and away from adipose storage.
- Conditioning, hardness, and vascularity: at body fat levels below ~15%, trenbolone's non-aromatizing anabolism combined with a testosterone base produces the dry, dense, vascular appearance associated with pre-contest phases; the hexa ester produces the same visual effect as acetate; it simply takes 3–4 weeks to reach peak blood levels rather than 1 week, making 10–14 week cycles more appropriate than the 8-week cycles typical with acetate.
- Strength increase disproportionate to body weight: trenbolone produces notable strength gains at doses where body weight change is minimal or absent; this is relevant for weight-class athletes, powerlifters, or users who need performance improvements without gaining scale weight; the mechanism involves both direct AR-mediated myofibrillar hypertrophy and IGF-1 upregulation.
- HPG axis suppression — testosterone base mandatory: like all trenbolone esters, hexahydrobenzylcarbonate rapidly and completely suppresses LH and FSH; a testosterone base is required on all trenbolone hexa cycles; Testabol Enanthate BD is the natural ester-aligned pairing for Trenabol Hexa BD in most cycle formats.
Who It's For
Trenabol Hexa BD is for experienced AAS users who have already used trenbolone acetate on at least one previous cycle, confirmed their individual response and side-effect profile with the short-acting ester, and are now choosing the hexa format specifically for injection frequency convenience or cycle-length suitability. The critical prerequisite is prior trenbolone acetate experience: running trenbolone for the first time with the ~14-day hexa ester removes the fast-exit option that acetate provides. If severe night sweats, cardiovascular distress, or mood effects emerge on a hexa cycle, they will persist for 2–3 weeks after the last injection rather than resolving in 5–7 days as they would with acetate.
The primary differentiator of Trenabol Hexa BD from Trenabol 100 BD (acetate) is ester half-life and its downstream consequences — not the anabolic or androgenic outcome, which is identical once the ester is cleaved. The scenario where hexa is clearly the better choice: a 12–14 week cycle paired with a long-ester testosterone base, where the user has confirmed trenbolone tolerance on a prior acetate run, prioritises injection convenience (twice-weekly vs EOD), and is not constrained by a PCT start deadline. For all first trenbolone runs, and for users who need fast cycle-exit flexibility (competition testing, health concerns), Trenabol 100 BD (acetate) is the appropriate choice. For users running longer mass or recomposition cycles with long-ester testosterone who want trenbolone in the stack without EOD injections, Trenabol Hexa BD is the practical format.
Users who should not choose Trenabol Hexa BD: anyone on their first trenbolone cycle (use acetate first to test individual response); users with an upcoming fixed cycle-end date within 10–12 weeks (the hexa ester requires 3–4 weeks to reach steady state and 3–4 weeks to clear post-cycle, consuming a large fraction of a short cycle window); users with cardiovascular risk factors; users who have previously experienced severe trenbolone side effects that required early cycle termination.
Trenabol Hexa vs Alternatives
| Compound | Key Differences | Choose Trenabol Hexa BD When | Choose Alternative When |
|---|---|---|---|
| Trenabol 100 BD (trenbolone acetate 100 mg/ml) | Identical anabolic/androgenic effect at equal weekly doses; acetate half-life ~2–3 days vs hexa ~14 days; acetate requires EOD injections vs hexa 1–2×/week; acetate reaches stable blood levels in 5–7 days vs hexa 3–4 weeks; acetate PCT window opens 3–5 days post-last-injection vs hexa 14–21 days; acetate allows fast cycle exit if side effects develop, hexa does not | Trenbolone tolerance already confirmed on prior acetate run; cycle is 12–14 weeks and pairs with long-ester testosterone; EOD injection schedule is impractical; no fixed PCT start deadline within 3 weeks of cycle end | First trenbolone cycle — always use acetate first; PCT timing is critical (competition, testing window, health concerns); cycle is 8–10 weeks (too short for hexa to justify the slow onset); preference for maximum dose-adjustment flexibility |
| Trenbolone 200 Dragon Pharma (trenbolone enanthate 200 mg/ml) | Both are long-ester trenbolones; enanthate half-life ~7 days vs hexa ~14 days; enanthate runs twice-weekly vs hexa once or twice-weekly; enanthate reaches steady state in ~2–3 weeks vs hexa ~3–4 weeks; enanthate PCT window opens at ~14 days vs hexa 14–21 days post-last-injection; both require confirmed trenbolone tolerance; enanthate at 200 mg/ml allows higher per-injection dose per volume; hexa has the longer ester benefit of even fewer concentration spikes | Maximum injection interval convenience (hexa once-weekly protocol viable); longest possible cycle with minimal injection frequency; ester alignment with very-long-acting testosterone undecanoate (if applicable) | Higher mg/ml concentration preferred (200 mg/ml vs 100 mg/ml for hexa); shorter cycle with fixed PCT window (enanthate clears ~7–14 days faster than hexa); Dragon Pharma brand preferred |
| Deca 300 Dragon Pharma (nandrolone decanoate 300 mg/ml) | Both are 19-Nor androgens with similar long half-lives (decanoate ~15 days vs hexa ~14 days); nandrolone aromatizes minimally while trenbolone does not aromatize at all; nandrolone AR affinity is much lower than trenbolone; nandrolone is a bulking compound with joint and collagen benefits; trenbolone is a conditioning compound with partitioning effects; nandrolone's side-effect burden is significantly more manageable for intermediate users; both require testosterone base and PCT | Goal is dry conditioning, pre-contest hardness, or recomposition in experienced athletes; body fat is below 15%; user has confirmed trenbolone tolerance on acetate previously | First 19-Nor compound addition; bulking cycle at caloric surplus; joint support needed; intermediate experience level where nandrolone's more forgiving side-effect profile is appropriate; maximum mass gain is the goal |
Combinations
| Goal | Primary | Support Compounds | Notes |
|---|---|---|---|
| Long-cycle cutting — ester-aligned with test enanthate | Trenabol Hexa BD 300 mg/wk 2×/week (wks 1–12) | Testabol Enanthate BD 400 mg/wk 2×/week + Anastrozole BD + Caberlin | Both esters are long-acting (hexa ~14 days, enanthate ~7 days); combine on the same twice-weekly injection day (Mon/Thu); test enanthate provides the mandatory testosterone base; Anastrozole BD is dosed against the testosterone component only (trenbolone does not aromatize); Caberlin 0.25 mg twice weekly from week 1; check E2 and prolactin at week 4; PCT starts 14–21 days after the last injection of both compounds |
| Pre-contest hardening — long-ester three-compound stack | Trenabol Hexa BD 300 mg/wk 2×/week (wks 1–12) | Testabol Depot BD (testosterone cypionate) 300 mg/wk 2×/week + Mastabol 200 BD (masteron enanthate) 400 mg/wk 2×/week + Caberlin | All three compounds are long esters (cypionate ~8 days, masteron enanthate ~10 days, hexa ~14 days) — all injectable on the same twice-weekly schedule; Mastabol 200 BD (drostanolone enanthate) adds tissue hardness and anti-estrogenic activity, reducing Anastrozole BD requirement; keep testosterone base at minimum effective dose (200–300 mg/wk) to minimise E2 contribution; this stack is suitable for cycles 12 weeks and above; monitor prolactin at week 5 |
| Lean recomposition — quality mass with minimal water | Trenabol Hexa BD 250 mg/wk 2×/week (wks 1–12) | Testabol Enanthate BD 400 mg/wk + Primobol Inject BD (methenolone enanthate) 400 mg/wk + Anastrozole BD + Caberlin | Trenabol Hexa BD + Primobol Inject BD provide strong anabolic activity with minimal estrogenic and progestogenic contribution; Primobol Inject BD (methenolone enanthate, ~10-day half-life) aligns well with twice-weekly dosing; testosterone enanthate as the base; Anastrozole BD dose is conservative given the low aromatizing load from the Primobolan component; good for experienced athletes prioritising lean mass over scale weight gains |
| Strength cycle — oral finisher in last 4–6 weeks | Trenabol Hexa BD 300 mg/wk 2×/week (wks 1–14) | Testabol Enanthate BD 500 mg/wk + Stanabol Tablets BD (stanozolol oral) 50 mg/day (wks 9–14) + Anastrozole BD + Caberlin | Trenabol Hexa BD + Testabol Enanthate BD form the 14-week injectable base; Stanabol Tablets BD added in the final 6 weeks for additional strength and hardness without added water; stanozolol compounds the HDL suppression already caused by trenbolone — mandatory lipid panel at week 10; do not extend oral stanozolol beyond 6 weeks; stop Stanabol Tablets BD and injectable compounds simultaneously; PCT starts 14–21 days after the last injection |
Side Effects & Management
| Side Effect | Frequency | How to Handle It |
|---|---|---|
| Prolonged persistence of side effects post-cycle | Specific to the long ester — the critical operational difference from acetate; any side effect present at cycle end will persist for 2–3 weeks as the hexa ester slowly clears | This is not a side effect to treat during the cycle but a risk-management consideration before starting: confirm individual trenbolone tolerance on a prior acetate run; have all management compounds (cabergoline, Anastrozole BD, antihypertensives) secured before the first injection; if night sweats, BP elevation, or mood effects are more severe than expected, the only option is to reduce dose or stop the cycle and wait for the ester to clear over 3–4 weeks |
| Night sweats and sleep disturbance | Very common, dose-dependent; same mechanism as acetate but blood levels are stable and consistent rather than fluctuating with EOD dosing; may be more constant in character than on acetate cycles | Cool sleeping environment; light bedding; typically tolerable and not medically hazardous; dose reduction is the only effective management strategy if severely disrupting sleep; do not confuse with fever — trenbolone night sweats are not accompanied by systemic illness signs |
| Prolactin elevation | Common at 300+ mg/week; same progestogenic mechanism as acetate; stable blood levels from hexa may produce a more consistent prolactin elevation pattern than the fluctuating levels on an EOD acetate protocol | Caberlin (cabergoline) 0.25 mg twice weekly from week 1; check prolactin bloodwork at week 4–5; if above reference range, increase Caberlin to 0.5 mg twice weekly; continue cabergoline for the first 1–2 weeks of PCT as hexa clears slowly; do not use an AI for prolactin-driven libido or ED symptoms — these require a dopamine agonist |
| HDL suppression and lipid disruption | Consistent; trenbolone causes severe HDL reduction; longer cycles (12–14 weeks) with hexa result in more cumulative lipid impact than 8-week acetate cycles; compounded by any stanozolol co-administration | Mandatory pre-cycle lipid baseline; omega-3 4 g/day throughout; mid-cycle lipid panel at week 6–7 (earlier than on an 8-week acetate cycle); if LDL exceeds 160 mg/dL: Atorvastatin 40 mg DP; avoid combining with oral 17-AA AAS (Dianabol, Anadrol) on the same cycle; post-cycle lipid panel at 6–8 weeks to confirm recovery |
| Blood pressure elevation | Common at higher doses; compounded by hematocrit rise and estrogen from the testosterone base | Weekly BP self-monitoring; target below 130/80 mmHg; manage E2 from testosterone with Anastrozole BD; Ecosprin 75 mg/day throughout; if BP persists above target: Amlip (amlodipine) 5 mg/day |
| Hematocrit elevation | Common; longer 12–14 week hexa cycles may produce more cumulative hematocrit rise than 8–10 week acetate cycles | Baseline CBC; mid-cycle at week 6–7; keep hematocrit below 52%; Ecosprin 75 mg/day when above 48%; blood donation if above 52% |
| Androgenic effects (acne, hair loss, aggression) | Common in androgen-sensitive individuals; trenbolone does not undergo 5AR reduction to a weaker metabolite — tissue androgenicity is sustained; finasteride does not reduce trenbolone's androgenic activity | Topical skincare; Accutane (isotretinoin) for severe cystic acne; Finasteride DP is ineffective against trenbolone androgenicity specifically, but reduces DHT from the testosterone base component; aggression and mood effects are dose-dependent — if unmanageable at entry-level doses (200–250 mg/week), trenbolone is not appropriate for that individual |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Prolactin | Baseline; week 4–5; post-PCT (4 weeks after SERM completion) | Keep within male reference range; above 20 ng/mL: increase Caberlin to 0.5 mg twice weekly; due to hexa's stable blood levels, prolactin readings on-cycle are more representative than on acetate where levels fluctuate with EOD dosing; continue cabergoline into early PCT until hexa clears fully |
| Estradiol (E2) | Baseline; week 4 (AI calibration for testosterone base); post-cycle | Target on cycle: 20–40 pg/mL; trenbolone does not contribute to E2; AI dose is calibrated purely against the testosterone base; long-ester testosterone on a hexa cycle means E2 responds to AI changes on a 1–2 week lag — titrate cautiously; over-suppressed E2 (below 15 pg/mL) causes joint pain and libido suppression that can be confused with prolactin-driven symptoms — check both in the same panel |
| Lipid panel (HDL, LDL, TG) | Baseline (mandatory); week 6–7 mid-cycle; post-cycle (6–8 weeks after) | HDL above 35 mg/dL on cycle; LDL below 130 mg/dL; longer 12–14 week cycles justify a mid-cycle lipid panel at week 6–7 rather than waiting until end; Atorvastatin DP if LDL exceeds 160 mg/dL; post-cycle lipid recovery expected within 6–12 weeks |
| Hematocrit & CBC | Baseline; week 6–7 on 12–14 week cycles | Hematocrit below 52%; hemoglobin below 17.5 g/dL; longer cycles accumulate more RBC elevation than 8-week runs — mid-cycle check is more important for hexa cycles than for short acetate cycles; Ecosprin 75 mg/day when above 48% |
| Blood pressure | Baseline; weekly self-monitoring during cycle | Target below 130/80 mmHg; longer cycle duration means prolonged exposure to any BP elevation — monitor weekly; address E2 and hematocrit first; add Amlip 5 mg/day if BP persists above target |
| LH + FSH | Baseline; post-PCT (4 weeks after SERM completion) | Post-PCT LH and FSH should return to pre-cycle baseline; hexa's long half-life means trenbolone levels remain suppressive for 3–4 weeks after the last injection — HPG axis stimulation from SERM therapy does not begin until the ester has cleared; document baseline before starting; persistent suppression at 4–6 weeks post-PCT warrants extended SERM therapy |
| Total testosterone | Baseline; post-PCT (4 weeks after completion) | Return to pre-cycle baseline post-PCT; longer cycles with trenbolone may result in slower HPG recovery than after short cycles or testosterone-only protocols; post-PCT total testosterone below 300 ng/dL at 6 weeks indicates incomplete recovery |
PCT
Trenbolone hexahydrobenzylcarbonate has a half-life of approximately 14 days. After the last injection, trenbolone levels fall by 50% every 14 days — measurable trenbolone is present for 3–4 weeks post-last-injection, and suppressive trenbolone levels persist for the first 2 weeks of that window. Wait 14–21 days after the last Trenabol Hexa BD injection before beginning SERM therapy. This is the fundamental difference from trenbolone acetate (3–5 day window) and represents the primary disadvantage of the hexa ester for time-sensitive situations.
If the cycle pairs Trenabol Hexa BD with a long-ester testosterone (Testabol Enanthate BD or Testabol Depot BD), the testosterone ester also requires a 14–21 day clearance window — the two compounds align on the same PCT start date. Stop all injectables on the same day and begin PCT 14–21 days later. If the cycle pairs Trenabol Hexa BD with testosterone propionate (Testabol Propionate BD), the testosterone propionate will clear in 3–5 days but PCT must still wait for the hexa to clear — 14–21 days from the last hexa injection.
Standard 4-week PCT protocol:
- Weeks 1–2: Tamoxifen BD 40 mg/day + Clomiphene BD 50 mg/day
- Weeks 3–4: Tamoxifen BD 20 mg/day + Clomiphene BD 25 mg/day
HCG blast before PCT: For 12–14 week hexa cycles, an HCG blast in the clearance window is recommended. Run HCG 5,000 IU Dragon Pharma at 2,500 IU on two days separated by 48 hours, beginning 5–7 days after the last injection and completing at least 5 days before the first SERM dose. This stimulates Leydig cell activity during the clearance window and supports faster HPG axis recovery once SERM therapy begins.
Cabergoline at PCT transition: Continue Caberlin 0.25 mg twice weekly through the first 2 weeks of PCT as hexa clears gradually — trenbolone-driven prolactin elevation resolves once the compound is fully eliminated, typically 3–4 weeks post-last-injection.
Practical Summary
- Confirmed trenbolone acetate tolerance is the prerequisite for hexa: the ~14-day half-life of Trenabol Hexa BD removes the fast exit option that acetate provides; any side effects present when the cycle ends will persist for 2–3 weeks as the ester clears; run Trenabol 100 BD (acetate) first, confirm your individual response, then use hexa on subsequent cycles for the injection convenience benefit.
- Pair with a long-ester testosterone for ester alignment: Testabol Enanthate BD or Testabol Depot BD are the natural bases for a hexa cycle; all long esters combined on the same twice-weekly injection schedule; this simplifies dosing, keeps injection frequency manageable, and aligns PCT timing so all compounds clear on the same schedule.
- PCT starts 14–21 days after last injection — plan the calendar before you start: a 12-week cycle with 14–21 days clearance + 4 weeks PCT = 18–20 weeks from first injection to the end of PCT; this is a substantial time commitment; have all PCT compounds secured (Tamoxifen BD, Clomiphene BD, HCG 5,000 IU DP) before the cycle begins.
- Cabergoline from week 1, continued into PCT clearance window: same principle as acetate — start Caberlin 0.25 mg twice weekly with the first injection; continue through the 2-week PCT clearance window while hexa is still clearing; check prolactin at week 4–5 and at 4 weeks post-PCT.
- Mid-cycle bloodwork at week 6–7 is more important than on short acetate cycles: longer 12–14 week cycles accumulate more cumulative lipid, hematocrit, and BP impact; catching a rising LDL or hematocrit at week 6 allows intervention before the end of the cycle; do not wait until cycle completion to run the first mid-cycle panel.
- 1,000 mg per vial at 300 mg/week = ~3.3-week supply: a 12-week cycle at 300 mg/week requires approximately 4 vials; secure full cycle supply before starting; do not begin a long-ester cycle without the complete supply on hand.
Trenabol Hexa BD from steroidwarehouse.com represents the original parabolan ester format — the same hexahydrobenzylcarbonate ester used in the Negma pharmaceutical product that defined trenbolone's reputation in competitive bodybuilding. For athletes who have already established their trenbolone response on acetate and are looking for the convenience of twice-weekly long-ester dosing in a 12–14 week conditioning cycle, Trenabol Hexa BD provides the same anabolic and conditioning profile as trenbolone acetate without the EOD injection schedule. The long half-life demands proportionally more careful planning at cycle-end — but for the experienced user with a structured protocol in place, it is a practical and effective format for extended pre-contest and recomposition cycles.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin S et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, especially when supraphysiologic testosterone was combined with resistance training | Bhasin S, et al. (1996) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations across anabolic-androgenic steroid use in sport | Hartgens F & Kuipers H (2004) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on anabolic-androgenic steroids including testosterone derivatives and injectable esterified AAS; covers androgen receptor mechanism, HPG-axis suppression, adverse effects, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone biosynthesis, androgen receptor signaling, HPG-axis regulation, aromatization, synthetic androgen pharmacology, and endocrine suppression from exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
What is Trenabol Hexa?
Trenabol Hexa is an injectable anabolic steroid (Trenbolone Hexahydrobenzylcarbonate) for muscle growth and fat loss; see What is Trenabol Hexa. It's potent—consult professionals for safe use.
What does Trenabol Hexa do?
It promotes muscle growth, strength, and fat loss; see What Does Trenabol Hexa Do. It enhances physique—monitor with labs.
Does Trenabol Hexa boost testosterone?
No, it suppresses testosterone; see Does Trenabol Hexa Boost Testosterone. Stack with testosterone—consult professionals.
How long does Trenabol Hexa stay in your system?
Detectable for ~2-3 months; see How Long Does Trenabol Hexa Stay in Your System. Monitor with professional guidance.
How do I take Trenabol Hexa?
100-300 mg/week, injected weekly or bi-weekly; see How to Take Trenabol Hexa. Start low—consult professionals for dosing.
How to cycle Trenabol Hexa?
8-12 weeks, 100-300 mg/week, PCT after 10-14 days; see How to Cycle Trenabol Hexa. Stack with testosterone—consult professionals.
What is Trenabol Hexa used for?
Trenabol Hexa is commonly associated with supporting lean muscle growth, strength development, body recomposition, muscle hardness, and overall physique conditioning.
How does Trenabol Hexa work?
Trenabol Hexa works by strongly binding to androgen receptors, promoting protein synthesis, nitrogen retention, and nutrient utilization, helping support muscle development and recovery.
Related Products
- Promotes significant muscle growth and strength gains.
- Enhances fat loss for a lean, defined physique.
- Improves muscle hardness and vascularity.
- Delivers sustained anabolic effects with minimal water retention.
- Promotes significant muscle growth and strength gains.
- Enhances fat loss and lean muscle retention.
- Boosts nitrogen retention for anabolic effects.
- Improves vascularity and hardness.
